Fig. 6.

LncGPR107-SRCAP-GPR107 can be targeted for liver TIC elimination. a 1 × 10⁶ primary cells were injected into BALB/c nude mice. When the volume of tumors were reach about 250 mm³, lncGPR107 ASO (antisense oligo) and control ASO were injected into tumors every two days. Tumor weight was measured one month later. n = 6 for each group. b 1 × 10⁶ lncGPR107 overexpressing cells were used for tumor propagation. n = 6 for each group. c 1 × 10⁶ indicated cells were used for tumor propagation, and the tumors were weighted one month later. n = 6 for each group. d The indicated tumors were obtained and GPR107 expression was examined through immunohistochemistry. Scale bars, 100 μm. e, f The indicated tumors were obtained and separated into individual cells for FACS. Ki67⁺ cells (e) and CD133⁺ liver TICs (f) were examined. n = 6 for each group, and the ratios of Ki67⁺ and CD133⁺ cells were shown as means±s.d. Experiments were repeated three times